Shanghai Bio-Heart’s Iberis Renal Denervation System Registered in Indonesia

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has issued an update.

Shanghai Bio-Heart announced that its subsidiary Shanghai AngioCare Medical Technology has completed registration of the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System in Indonesia, supported by commercialization partner Biosensors International Group. Iberis® is currently the only renal denervation product globally approved for both transradial and transfemoral approaches, a combination the company says can make RDN procedures safer, more effective and cheaper, underpinning its ambition to shift RDN towards outpatient settings worldwide and potentially strengthening its competitive positioning in international cardiovascular device markets, although the company cautions there is no guarantee the system will be successfully developed and marketed.

The most recent analyst rating on (HK:2185) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Shanghai Bio-Heart Biological Technology Co., Ltd. Class H stock, see the HK:2185 Stock Forecast page.

More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H

Shanghai Bio-Heart Biological Technology Co., Ltd. is a China-based medical technology company focused on cardiovascular intervention, developing innovative devices such as renal denervation (RDN) systems through its subsidiary Shanghai AngioCare Medical Technology. The group targets global markets, particularly the EU, Asia-Pacific and Latin America, often leveraging partnerships with international cardiovascular device companies to commercialize its products.

Average Trading Volume: 423,336

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.47B

For detailed information about 2185 stock, go to TipRanks’ Stock Analysis page.